ArticleFrontiers in cardiovascular medicine2026
LVEF-based phenotyping in very old adults hospitalised for heart failure: cardiological discrimination, shared geriatric burden, and treatment gaps.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methods: We conducted a retrospective observational cohort study in a cardiogeriatric unit to compare cardiological, geriatric, biological, and therapeutic profiles across LVEF phenotypes in very old adults hospitalised for heart failure (HF). All patients with HF and classifiable LVEF were included and categorised according to 2021 European Society of Cardiology (ESC) criteria as heart failure with reduced ejection fraction (HFrEF, ≤40%), heart failure with mildly reduced ejection fraction (HFmrEF, 41%-49%), and heart failure with preserved ejection fraction (HFpEF, ≥50%). The primary objective was to describe and compare cardiological, biological, geriatric, and therapeutic profiles across LVEF phenotypes. The comprehensive geriatric assessment (CGA)-derived geriatric indicator count was used as a descriptive measure of multidimensional geriatric burden, and not as a validated frailty instrument. Results: Among 1,299 patients [median age 88.5 years (IQR 82.5-92.2)], HFpEF predominated (58.8%). Despite markedly different cardiological profiles, CGA-derived geriatric burden was similar across phenotypes: the study-defined geriatric indicator count was identical in all groups [median 2 (1-3); Conclusions: LVEF category remains central to pharmacological treatment selection but does not discriminate CGA-derived geriatric burden or iron deficiency burden in very old HF patients. These findings support systematic comprehensive geriatric assessment and iron status assessment regardless of LVEF phenotype, alongside phenotype-informed pharmacological optimisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.